drugset / Trial / NCT00368927

Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia

NCT00368927

Phase 2 Completed 61 enrolled National Cancer Institute (NCI)
RandomizedParallel-groupDouble-blindPrevention

Summary

This randomized phase II trial is studying sulindac to see how well it works compared to a placebo in preventing lung cancer in current or former smokers with bronchial dysplasia. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of sulindac may prevent lung cancer from forming in patients with bronchial dysplasia. It is not yet known whether sulindac is more effective than a placebo in preventing lung cancer in patients with bronchial dysplasia.

Timeline

Start
2006-08
Primary completion
2010-05
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Sulindac Small molecule 150 mg Oral